ArticleJournal of virology2005
Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Review
- Review
- Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19.Postgraduate medical journal · 2021Article
- Nanocarrier vaccines for SARS-CoV-2.Advanced drug delivery reviews · 2021Article
- The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.International immunopharmacology · 2021Review
- Current advances in the development of SARS-CoV-2 vaccines.International journal of biological sciences · 2021Review
- Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19.Immune network · 2020Review
- Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.Infectious diseases and therapy · 2020Review
- Adjuvants for Coronavirus Vaccines.Frontiers in immunology · 2020Review
- IRAK-M alters the polarity of macrophages to facilitate the survival of Mycobacterium tuberculosis.BMC microbiology · 2017Article
- Evaluation of candidate vaccine approaches for MERS-CoV.Nature communications · 2015Article
- Current advancements and potential strategies in the development of MERS-CoV vaccines.Expert review of vaccines · 2014Review
- MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.International immunopharmacology · 2012Article
- Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.Immunology · 2010Article
- Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome.Journal of virology · 2009Article
- Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.Clinical and vaccine immunology : CVI · 2009Article
- Article
- Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice.Virology · 2008Article
- Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.Virus research · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Although the initial isolates of the severe acute respiratory syndrome (SARS) coronavirus (CoV) are sensitive to neutralization by antibodies through their spike (S) glycoprotein, variants of S have since been identified that are resistant to such inhibition. Optimal vaccine strategies would therefore make use of additional determinants of immune recognition, either through cellular or expanded, cross-reactive humoral immunity. Here, the cellular and humoral immune responses elicited by different combinations of gene-based and inactivated viral particles with various adjuvants have been assessed. The T-cell response was altered by different prime-boost immunizations, with the optimal CD8 immunity induced by DNA priming and replication-defective adenoviral vector boosting. The humoral immune response was enhanced most effectively through the use of inactivated virus with adjuvants, either MF59 or alum, and was associated with stimulation of the CD4 but not the CD8 response. The use of inactivated SARS virus with MF59 enhanced the CD4 and antibody response even after gene-based vaccination. Because both cellular and humoral immune responses are generated by gene-based vaccination and inactivated viral boosting, this strategy may prove useful in the generation of SARS-CoV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.